Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028769 · ClinicalTrials.gov registry record · Phase 2
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00028769 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 41 participants.
The verdict
NCT00028769, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus hormone therapy in treating patients who have metastatic prostate cancer.
Interventions
- DRUG goserelin
- DRUG etoposide
- DRUG bicalutamide
- DRUG flutamide
- DRUG estramustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2001-12 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028769
The ClinicalTrials.gov registry entry for NCT00028769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which goserelin is the first listed.
NCT00028769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028769 about?
NCT00028769 is a clinical study titled "S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens. C...
What is the current status of trial NCT00028769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2001-12. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00028769?
The interventions under investigation include: goserelin (DRUG), etoposide (DRUG), bicalutamide (DRUG), flutamide (DRUG), estramustine (DRUG).
Who is sponsoring clinical trial NCT00028769?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.